Trexquant Investment’s Clovis Oncology, Inc. CLVS Stock Holding History

Trexquant Investment’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-23,732	Closed	-$138K	–	1611
2021 Q2	$138K	Sell	23,732 -140,979	-86%	-$826K	0.01%	980
2021 Q1	$1.16M	Buy	+164,711	New	+$1.1M	0.11%	246
2019 Q3	–	Sell	-10,567	Closed	-$157K	–	1188
2019 Q2	$157K	Sell	10,567 -464	-4%	-$8.38K	0.01%	710
2019 Q1	$274K	Buy	+11,031	New	+$277K	0.02%	772
2018 Q2	–	Sell	-57,054	Closed	-$3.01M	–	1322
2018 Q1	$3.01M	Buy	+57,054	New	+$3.33M	0.21%	139
2017 Q3	–	Sell	-6,100	Closed	-$571K	–	1099
2017 Q2	$571K	Buy	+6,100	New	+$373K	0.16%	197
2016 Q4	–	Sell	-24,159	Closed	-$871K	–	1190
2016 Q3	$871K	Buy	+24,159	New	+$518K	0.19%	151
2016 Q1	–	Sell	-90,561	Closed	-$3.17M	–	1242
2015 Q4	$3.17M	Buy	+90,561	New	+$5.84M	0.28%	65
2015 Q2	–	Sell	-8,330	Closed	-$618K	–	1314
2015 Q1	$618K	Buy	+8,330	New	+$588K	0.06%	612

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Trexquant Investment's CLVS Position: Q3 2021 in Review

Trexquant Investment sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 23,732 shares — an estimated $138K sold.

Trexquant Investment first reported a position in CLVS in Q1 2015 and held it in 9 quarters. The position peaked at $3.17M in Q4 2015. 158 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

Trexquant Investment reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
Trexquant Investment sold 23,732 Clovis Oncology, Inc. shares in Q3 2021, an estimated $138K.
Trexquant Investment first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 9 quarters.
Trexquant Investment's Clovis Oncology, Inc. position peaked at $3.17M in Q4 2015.
158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on Trexquant Investment's 13F filing for Q3 2021, filed 12 Nov 2021.